Affiliate disclosure
We earn a commission if you sign up with Innerwell through the links on this page. It did not buy a favourable review — as the rating and the section immediately below make clear.
Innerwell sells at-home sublingual ketamine programs for depression, at $54 to $125 a dose depending on plan and insurance. Before any of the pricing matters, there is a federal safety communication that applies directly to this category and that most buyers have never seen.
The FDA Warning
On 10 October 2023 the FDA warned patients and health care providers about the risks of compounded ketamine products for psychiatric conditions.
Using them without a health care provider monitoring for sedation, dissociation and changes in vital signs may put patients at risk of serious adverse events. The agency specifically noted that at-home administration carries additional risk because no provider is present. It cited an April 2023 adverse event report of respiratory depression after compounded oral ketamine taken outside a health care setting.
Two further facts from the same communication. Ketamine is not FDA-approved for any psychiatric indication — not depression, not anxiety, not PTSD, not OCD — despite widespread marketing for all of them. And the FDA noted growing interest specifically in the sublingual and oral compounded forms, which is exactly the format sold for at-home use.
This does not mean at-home ketamine is worthless or that everyone using it is in danger. There is a real approved product in this space — esketamine nasal spray — and it is administered in certified health care settings with observation afterwards, precisely because of these risks. The distinction between that and taking a compounded tablet alone at home is the entire subject of the warning.
Two additional considerations that belong in any honest assessment: ketamine is a Schedule III controlled substance with recognised misuse potential, and long-term use is associated with urinary tract and bladder toxicity. Neither is a reason nobody should ever use it. Both are reasons this is not a casual purchase.
The Same Pattern This Site Tracks in GLP-1s
Readers here will recognise the shape of this immediately. A compounded drug, not FDA-approved as a finished product, sold direct to consumers by telehealth for an indication the agency has not approved, at a price far below the supervised alternative.
That is the argument we make throughout our compounded versus brand-name guide and applied again to compounded hormone creams in our Winona review. The reasoning does not change because the category does.
If anything the stakes are higher here. A compounded semaglutide of uncertain potency is a serious problem, but it does not sedate you. A compounded dissociative taken without monitoring can.
Pricing — and the Bundles That Are Not Discounts
| Plan | With insurance | Self-pay |
|---|---|---|
| Foundation — 8 doses | $599 ($75/dose) | $998 ($125/dose) |
| Extended — 24 doses | $1,299 ($54/dose) | $1,999 ($83/dose) |
Insurance is accepted in select states including California, New York, Washington, Colorado, Texas and Illinois. At $54 to $88 a dose with coverage, this is among the cheapest professionally supervised at-home ketamine available, and considerably below IV clinic pricing.
A detail worth checking yourself: the continuation bundles save you nothing.
Weekly is $88 per session, or $700 for eight — which is $87.50 each. Bi-weekly is $138 per session, or $550 for four — $137.50 each. Monthly is $200 per session, or $400 for two — $200 each. Every bundle is the per-session price multiplied out, to the cent.
That is not dishonest — the prices are published and the arithmetic is there for anyone to do. But a bundle normally implies a discount for committing up front, and here it buys you a prepayment obligation with no saving attached. Given that the same coverage reports refund delays, paying per session rather than in advance looks like the better structure.
The Billing Complaints
Independent coverage reports BBB complaints centred on billing and refunds, including patients charged before completing screening and delays in getting money back. One reviewer described the billing as opaque, with real costs higher than advertised once clinician visits and program requirements were counted.
Being charged before screening is complete is the specific item to watch, because screening is the safeguard. If you are billed before anyone has established that this treatment is appropriate for you, the commercial process has run ahead of the clinical one. Establish before paying anything what happens to your money if screening rules you out.
Why This Is on a Weight Site at All
Honestly: the connection is indirect, and we would rather say so than manufacture one. Depression and obesity are bidirectionally associated — each raises the risk of the other — and treatment- resistant depression is a genuine barrier to sustaining any health change. That is the whole of the link.
What is directly relevant is the regulatory pattern. Our readers are the target market for compounded medications sold by telehealth, and recognising that pattern here makes it easier to recognise elsewhere. For depression treatment specifically, our Talkiatry review covers insurance-based psychiatry and Octave covers therapy — both are first-line where ketamine is not.
Pros and Cons
Pros
- $54–$88 a dose with insurance, well below IV clinics
- Insurance accepted in several states — unusual in this category
- Clinician involvement rather than pure mail-order
- Per-session continuation options exist
- Serves treatment-resistant depression, a real unmet need
Cons
- FDA warned specifically about unmonitored compounded ketamine
- Ketamine is not FDA-approved for any psychiatric indication
- At-home use means no provider present for sedation events
- Schedule III controlled substance with misuse potential
- Long-term use linked to bladder and urinary tract toxicity
- BBB complaints on billing, pre-screening charges and refunds
- Bundles offer no discount over per-session pricing
Who Should Use It
Consider it only if you have genuinely treatment-resistant depression, have worked through first-line options with a psychiatrist, have read the FDA communication in full, and have a clinician who knows you and supports this specific route.
Ask about the alternative before you buy. Esketamine nasal spray is FDA-approved for treatment-resistant depression and is given in certified settings with post-dose observation. It is less convenient and may cost more. It is also the version with an approval behind it, and your psychiatrist can tell you whether you qualify.
Do not start here. If you have not tried therapy or a properly reviewed medication regimen, those come first — see Octave and Talkiatry. And if you have a history of psychosis, substance misuse, uncontrolled blood pressure, or you would be dosing with nobody else in the home, this is not the right format.
Limitations of This Review
Based on published pricing and independent coverage checked on 7 August 2026. We could not verify the BBB complaints individually, establish what monitoring or supervision Innerwell actually provides during dosing, confirm current state availability, or determine which insurers are accepted. We could not confirm whether the ketamine dispensed is compounded — the FDA warning addresses compounded products, and that question is worth putting to Innerwell directly. Safety statements come from the FDA and published clinical sources, not from Innerwell, and describe ketamine generally rather than this program. Nothing here is medical advice, and depression treatment decisions belong with a clinician who knows you.
Frequently Asked Questions
Is at-home ketamine FDA-approved?
No. Ketamine is not FDA-approved for any psychiatric indication, and in October 2023 the FDA warned specifically about compounded ketamine used without provider monitoring for sedation, dissociation and vital sign changes. Esketamine nasal spray is approved for treatment- resistant depression, but is given in certified settings with observation.
What does Innerwell cost?
The Foundation Plan is 8 doses at $599 with insurance or $998 self-pay; the Extended Plan is 24 doses at $1,299 or $1,999. That is $54 to $125 a dose. Continuation runs $88 weekly, $138 bi-weekly or $200 monthly per session.
Do the multi-dose bundles save money?
No. Each continuation bundle is exactly the per-session price multiplied by the number of doses — $700 for eight weekly sessions at $88 is $87.50 each, and the bi-weekly and monthly bundles work out identically. You gain nothing but a prepayment obligation.
Does ketamine help with weight?
It is not a weight treatment and we make no such claim. Depression and obesity are bidirectionally associated, which is the only connection — and depression has first-line treatments that come well before this one.
Verdict
2.8 / 5
Cheap for the category and genuinely insurance-friendly, but the format is the one the FDA issued a warning about, the drug is unapproved for the indication, and the billing complaints land on the screening step that is supposed to protect you.
Treatment-resistant depression is a serious problem and the people seeking this out are usually not out of options by choice. We are not dismissing it, and the price against an IV clinic is real.
But convenience is the specific thing the FDA warning is about. Being alone when a dissociative takes effect is not a minor difference from being observed, and the pattern — compounded, not approved for the use, sold direct, cheaper than the supervised version — is one this site recognises from a different aisle. Read the FDA communication before you decide, and ask your psychiatrist about the approved option first.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from Innerwell's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: August 7, 2026
Ask About the Approved Version First
Esketamine is FDA-approved for treatment-resistant depression and given with observation. A psychiatrist can tell you whether you qualify — and whether first-line options have really been exhausted.